Engineered cord blood cells take aim at stubborn colorectal cancer
NCT ID NCT06358430
First seen Jun 26, 2026 · Last updated Aug 05, 2026 · Updated 5 times
Summary
This early-phase trial tests a new combination therapy for people with colorectal cancer who have minimal residual disease (MRD) — tiny amounts of cancer left after treatment. The approach uses specially engineered immune cells from cord blood (TROP2-CAR-NK cells) plus a targeted drug called cetuximab. The study will enroll 42 adults to find the safest dose and check for side effects.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- TROP2-CAR-NK cells (engineered immune cells from cord blood) plus cetuximab
- What this could lead to
- If it works, this could point toward a way to eliminate leftover cancer cells after standard treatment, potentially preventing colorectal cancer from coming back.
- What could go wrong
- This is a very early Phase 1 trial with only 42 people, so the main goal is safety, not proof of effectiveness. The treatment involves strong chemotherapy and immune cells, which can cause serious side effects.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for COLORECTAL CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
MD Anderson Cancer Center
Houston, Texas, 77030, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a plasma beam stop colon polyps from coming back?
- A stitch in time: could a device make abdominal closure safer?
- Can we predict chemo brain before it happens?
- Your gut bacteria might reveal hidden cancer risk
- Can a smart digital program restore sleep for cancer survivors?
- Can a new infusion drug shrink Hard-to-Treat tumors?